Aduro Biotech, Inc. (NASDAQ:ADRO) insider Thomas W. Dubensky sold 50,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $11.38, for a total value of $569,000.00. Following the transaction, the insider now owns 80,812 shares in the company, valued at approximately $919,640.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Aduro Biotech, Inc. (NASDAQ:ADRO) traded up 1.79% during trading on Friday, reaching $11.35. The company’s stock had a trading volume of 379,430 shares. The stock’s 50 day moving average is $12.44 and its 200 day moving average is $10.98. Aduro Biotech, Inc. has a 12 month low of $8.75 and a 12 month high of $16.15. The company’s market cap is $846.85 million.

Aduro Biotech (NASDAQ:ADRO) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.02. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The business had revenue of $5.90 million for the quarter, compared to the consensus estimate of $3.98 million. During the same period in the previous year, the firm earned $0.03 EPS. The company’s revenue was down 84.9% compared to the same quarter last year. On average, equities analysts expect that Aduro Biotech, Inc. will post ($1.37) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/aduro-biotech-inc-adro-insider-thomas-w-dubensky-sells-50000-shares.html.

A number of large investors have recently modified their holdings of the stock. Wellington Management Group LLP boosted its stake in shares of Aduro Biotech by 9.1% in the first quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock worth $101,571,000 after buying an additional 791,770 shares during the last quarter. Norges Bank acquired a new stake in shares of Aduro Biotech during the fourth quarter worth about $3,266,000. JPMorgan Chase & Co. boosted its stake in shares of Aduro Biotech by 283.7% in the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after buying an additional 275,295 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Aduro Biotech by 330.5% in the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock worth $2,545,000 after buying an additional 181,734 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Aduro Biotech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after buying an additional 160,800 shares during the last quarter. 35.60% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently weighed in on the company. HC Wainwright assumed coverage on Aduro Biotech in a research note on Monday, May 1st. They set a “buy” rating and a $18.00 target price on the stock. BidaskClub upgraded Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Cowen and Company assumed coverage on Aduro Biotech in a research note on Tuesday, July 18th. They set an “outperform” rating on the stock. Zacks Investment Research lowered Aduro Biotech from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 2nd. Finally, Canaccord Genuity set a $30.00 target price on Aduro Biotech and gave the stock a “buy” rating in a research note on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $19.00.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.